Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left"><i>N </i></td><td align="left" colspan="2">31</td></tr><tr><td align="left">Age (Yr) </td><td align="left" colspan="2">65.0 </td></tr><tr><td align="left">Median (range)</td><td align="left" colspan="2">(35–86)</td></tr><tr><td align="left">Sex (no.) male/female</td><td align="left" colspan="2">25/6</td></tr><tr><td align="left">Disease (<i>n</i>)</td><td align="left">CBD stone <br/>Chronic pancreatitis <br/>Bile duct stricture <br/>Autoimmune pancreatitis (AIP)<br/>Adenomyomatosis (ADM) of the gallbladder <br/>Pancreatic pseudocyst <br/>Pancreaticobiliary maljunction <br/>Pancreatic duct stricture </td><td align="center">13 <br/>6 <br/>4<br/>2<br/>2<br/>2<br/>1<br/>1</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Clinical characteristics of patients with benign disease.

Journal of Oncology

tab2

Table 2

Table 2: Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers 